KEYTRUDA’s recent success in triple-negative breast cancer validates I-SPY 2 adaptive platform approach to phase II clinical trials

Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity & differential therapeutic responses

AI reveals new breast cancer types that respond differently to treatment

Could a form of cell death enhance cancer immunotherapy?

July 29, 2019 0

Hollings clinical scholar researches novel triple-negative breast cancer treatments

Predicting breast cancer response with ‘high’ TMB

Breast cancer experts highlight key takeaways from the 2019 ASCO annual meeting

First positive results reported in TAPUR™ study cohorts

Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy